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Healthy Exosomes and their Effects on Diabetic Cardiomyocytes
Miguel Garza, Genaro Ramírez-Correa, María de Lourdes Garza-Rodríguez, Andres J Medina
University of Texas Rio Grande Valley School of Medicine Department of Molecular Science.

Abstract. Extracellular Vesicles, and more specifically, exosomes, are essential for effective cellto-cell communication in a wide variety of tissues. In the last couple of decades, these
nanovesicles have been proven to be active participants and regulators in many disease
processes; therefore, their therapeutic effects have been widely studied and proven in various
cardiovascular diseases both, in vitro and in vivo. Thus, this study aims at assessing the effects of
running healthy mice exosomes on cardiomyocyte and cardiac tissue samples obtained from
diabetic mice. Here, we successfully extract exosomes from mice plasma and detect their
presence through the use of anti-CD9 and anti-CD81 antibodies. Further work includes
concentrating exosome presence and utilizing a wider variety of exosome-specific antibodies, as
well as exploring techniques for more effective exosome extraction from plasma.

Introduction. Cell-to-cell communication is central in both, the proper functioning of every
working tissue in our body, as well as in every pathophysiological process underlying every
disease. One of the methods through which cells effectively communicate with each other is
using extracellular vesicles (EVs), which are ubiquitous and essential information carriers that
transport proteins, lipids, signaling molecules, and nucleic material with high specificity. A
specific type of EVs, called exosomes, are nanosized EVs of endosomal origin known to be
involved in the regulation of many pathophysiological processes throughout our whole body
(Barile & Vassalli, 2017). The importance of these types of EVs has been increasingly proven to
be more relevant, being involved directly in the pathophysiology of many disease processes,

including tumorigenesis, inflammation, autoimmune diseases, neurodegenerative processes, and
cardiomyopathies (EL Andaloussi et al., 2013). Due to their many crucial roles in regulating
disease processes, exosome use as a delivery agent of therapeutic components has increasingly
popularized in the last couple of decades, with many clinical trials being conducted in a wide
range of diseases. Most specifically, exosome benefits and potential therapeutic uses have been
proven to have beneficial effects on different cardiovascular diseases. EVs have proven effective
in initiating anti-apoptotic activity in cardiomyocytes, inducing proangiogenic activities,
improving cardiac tissue function post-myocardial infarction (MI) in vivo, and scar reduction
with improved cardiac function in vivo (Barile et al., 2014). Hence in this study, the focus is to
extract exosomes from healthy running mice, with the purpose of culturing diabetic mice
cardiomyocytes with healthy exosomes, to then assess cardiomyocyte function changes and
compare them to control diabetic mice.
Materials and Methods. A total of 4 experimental mice were subject to a running wheel for a
period of 6 weeks, with constant measurement of the number of spins and distance run. Plasma
was then isolated from each mouse, as well as from 4 wild-type mice. Plasma extraction worked
by ethically sacrificing mice by dislocation after isoflurane anesthesia in an oxygen chamber; the
heart was cut from the right atria and blood was collected directly from the thoracic cavity using
a tuberculin syringe previously impregnated with sodium citrate anticoagulant. Collected blood
was placed on 100µL sodium citrate anticoagulant. Blood sat at room temperature for 30 minutes
before centrifuging at 2500g for 15 minutes at 4oC. Plasma samples only from wild-type mice
were then fractioned by size using Izon Automatic Fraction Collector (AFC), dividing each
plasma sample into 12 different fractions; PBS was the buffer of choice for fractions. Protein
concentration for each fraction was determined using Lowry Protein Assay after lysing each

fraction using 1X RIPA buffer and proteinase inhibitor. After the determination of
concentrations, only fractions 10, 11, and 12 were considered for subsequent steps. Western Blot
was performed using PVDF transfer membrane using iBlot2 Dry Blotting System; anti-CD9 and
anti-CD81 1:1000 was used as primary antibodies incubated overnight at 4oC, and anti-Rabbit
IgG HRP-linked 1:2000 as secondary antibody incubated for 1 hour at room temperature. Magic
Mark and Sea Blue ladders were utilized. Super signal West Pico PLUS Chemiluminescent
substrate was used for revelation. Coomassie Blue and Red Ponceau stains were used for visual
examination of gel and PVDF membrane, respectively. In the last trial, samples were
concentrated using Eppendorf Vacufage Plus, set at 60oC for 20 minutes to yield a 5x
concentration.
Results. In the first trial, there was clear evidence of the presence of sufficient protein based on
the Lowry Protein Assay (Tables 1 and 2).

Tables 1 and 2. Lowry Protein Assay for the 4 wild-type mice samples. Significant protein concentration was
observed on fractions 8 and above, where only 10, 11, and 12 were considered to maximize yield.

However, when loading into the gel, only 1µL of the sample was used by convention for running
the gel, yielding a nearly empty membrane. Thus, on trial 2, the full amount of 65µL of protein
concentrate was added to the running solution, yielding clear evidence of the presence of the
proteins of interest at 26kDa on Coomassie stain and on WB revelation (Figures 1 - 6).
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Figures 1, 2, and 3, anti-CD9 membranes. Figure 1 (left) depicts the Coomassie Blue stain of the gel. The red
arrow shows bands of interest at 26kDa. Figure 2 in the middle depicts a nitrocellulose membrane stained with
Ponceau Red. Figure 3 on the right depicts the final reveal of WB, with bands of the protein of interest pointed by
the red arrow; notice the darker gray stain on the right side of the membrane.
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Figures 4, 5, and 6, anti-CD81 membranes. Figure 4 (left) depicts the Coomassie Blue stain of the gel. The red
arrow shows bands of interest at 26kDa. Figure 5 in the middle depicts a nitrocellulose membrane stained with
Ponceau Red. Figure 6 on the right depicts the final reveal of WB, with bands of the protein of interest pointed by
the red arrow; notice the lighter gray stain on the right side of the membrane.
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However, the container used to incubate antibodies on the membrane was not appropriate,
yielding an unevenly stained membrane; based on membrane results, it was determined that the
whole
Western Blot was to be performed again in a flat container for better results. On trial 3, the
Western Blot yielded better results (Figures 7 - 12), with bands confirming the presence of
exosomes. Using an even surface and utilizing PVDF membrane yielded cleaner results.
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Figures 7, 8, and 9, anti-CD9 membranes. Figure 7 (left) depicts the Coomassie Blue stain of gel. The red arrow
shows bands of interest at 26kDa. Figure 8 in the middle depicts the PVDF membrane stained with Ponceau Red.
Figure 9 on the right depicts the final reveal of WB, with bands of the proteins in interest pointed by the red arrow
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Figures 10, 11, and 12, anti-CD81 membranes. Figure 10 (left) depicts the Coomassie Blue stain of the gel. The
red arrow shows bands of interest at 26kDa. Figure 11 in the middle depicts a nitrocellulose membrane stained with
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Ponceau Red. Figure12 on the right depicts the final reveal of WB, with bands of the protein of interest pointed by
the red arrow.

In the last trial, after concentrating all samples, the Western blot yielded no results due to
technical and mechanical difficulties.
Discussion. From the samples obtained, we were successfully able to confirm the presence of
exosomes from the plasma samples; although the results on the Western Blot seemed faint, both
anti-CD9 and anti-CD81 antibodies seemed effective in proving the presence of exosomes at
around the 26kDa size; however, there is still some work to be done to concentrate protein
samples more effectively, and more exosome-specific antibodies to be tested. The last trial,
attempted solely with the purpose of concentrating samples, proved ineffective in doing so; we
hypothesize that the samples were unable to run due to the high salt content of the RIPA buffer
utilized to lyse the samples. Further attempts to concentrate the samples will be done in earlier
steps of the procedure, to concentrate before adding any saline buffers. Lastly, upon being able to
concentrate exosomes successfully, we plan to transition to the process of isolation and to culture
of cardiomyocytes in vitro, with the goal to slowly transition to exosome extraction from healthy
human subjects and culturing those to pathological human heart tissue.
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